Latest news
25 items- INSIDERDirector Ayurmaya Capital Management Company, Lp returned 9,334,735 shares to the company (SEC Form 4)4 - ACELYRIN, Inc. (0001962918) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by ACELYRIN INC.SCHEDULE 13D/A - ACELYRIN, Inc. (0001962918) (Subject)
- INSIDERChief Executive Officer Kim Mina was granted 89,526 shares and returned 770,833 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ACELYRIN, Inc. (0001962918) (Issuer)
- INSIDERSEC Form 4 filed by Director Cozadd Bruce C4 - ACELYRIN, Inc. (0001962918) (Issuer)
- INSIDERChief Legal Officer Murugan Amar returned 121,587 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ACELYRIN, Inc. (0001962918) (Issuer)
- INSIDERDirector Seidenberg Beth C returned 9,850,729 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ACELYRIN, Inc. (0001962918) (Issuer)
- INSIDERChief Medical Officer Mpofu Shephard returned 121,789 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ACELYRIN, Inc. (0001962918) (Issuer)
- INSIDERDirector Gosebruch Henry O returned 50,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ACELYRIN, Inc. (0001962918) (Issuer)
- INSIDERDirector Machado Patrick returned 14,675 shares to the company (SEC Form 4)4 - ACELYRIN, Inc. (0001962918) (Issuer)
- INSIDERDirector Svoronos Dawn returned 15,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ACELYRIN, Inc. (0001962918) (Issuer)
- INSIDERDirector Becker Daniel J. returned 2,999 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ACELYRIN, Inc. (0001962918) (Issuer)
- INSIDERSEC Form 4 filed by Director Tetrault Lynn A.4 - ACELYRIN, Inc. (0001962918) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by ACELYRIN INC.SCHEDULE 13D/A - ACELYRIN, Inc. (0001962918) (Subject)
- SECSEC Form EFFECT filed by ACELYRIN INC.EFFECT - ACELYRIN, Inc. (0001962918) (Filer)
- SECSEC Form POS AM filed by ACELYRIN INC.POS AM - ACELYRIN, Inc. (0001962918) (Filer)
- SECSEC Form S-8 POS filed by ACELYRIN INC.S-8 POS - ACELYRIN, Inc. (0001962918) (Filer)
- SECSEC Form S-8 POS filed by ACELYRIN INC.S-8 POS - ACELYRIN, Inc. (0001962918) (Filer)
- SECSEC Form S-8 POS filed by ACELYRIN INC.S-8 POS - ACELYRIN, Inc. (0001962918) (Filer)
- SECSEC Form 25-NSE filed by ACELYRIN INC.25-NSE - ACELYRIN, Inc. (0001962918) (Subject)
- SECACELYRIN INC. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Completion of Acquisition or Disposition of Assets8-K - ACELYRIN, Inc. (0001962918) (Filer)
- INSIDERChief Executive Officer Kim Mina was granted 30,851 shares and covered exercise/tax liability with 21,297 shares, increasing direct ownership by 1% to 681,307 units (SEC Form 4)4 - ACELYRIN, Inc. (0001962918) (Issuer)
- SECSEC Form 8-K filed by ACELYRIN INC.8-K - ACELYRIN, Inc. (0001962918) (Filer)
- SECSEC Form 10-Q filed by ACELYRIN INC.10-Q - ACELYRIN, Inc. (0001962918) (Filer)
- PRAlumis Stockholders Approve Merger with ACELYRINSOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with ACELYRIN, INC. (NASDAQ:SLRN) at its Special Meeting of Stockholders. Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, "We thank our stockholders for their support for the merger and with this milestone now complete, we are moving expeditious
- PRACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated DiseasesLOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that at the Company's special meeting of stockholders held earlier today, its stockholders voted to approve the adoption of the Company's merger agreement with Alumis Inc. (NASDAQ:ALMS). As previously announced, under the terms of the amended merger agreement, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned at the closing of the transaction. "We appreciate our stockholders' support for our merger
SLRN FAQ
6 questionsWhere does SLRN stock trade?
ACELYRIN INC. (SLRN) is listed on NASDAQ.What sector and industry is SLRN in?
ACELYRIN INC. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did ACELYRIN INC. go public?
ACELYRIN INC. (SLRN) completed its IPO in 2023.What are analysts saying about SLRN?
ACELYRIN INC. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral with a $600.00 price target on 2024-08-14.What companies are similar to SLRN?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare SLRN side-by-side with any of them on Quantisnow.How can I track SLRN on Quantisnow?
Quantisnow aggregates ACELYRIN INC.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SLRN to receive live email and push alerts on every new disclosure.